Ilektra A. Mavroeidi

Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study

Sabrina Welland, A Zöller, Ilektra A. Mavroeidi, Aurelie Tomczak et autres

Background & Aims Biliary tract cancers (BTC) comprise a group of aggressive malignancies with limited therapeutic options. Owing to the high frequency of actionable genomic alterations (GA) and the availability of targeted therapies, molecular testing has gained increasing importance; however, its implementation …

de, at, ca (code pays fourni par la source)

301P Homologous recombination repair (HRR) deficiency in biliary tract cancers: Clinical implications in subsequent therapy lines and correlation with platinum sensitivity

Ilektra A. Mavroeidi, T.W. Seyed Mohammad, Gerald Webersinke, Jonathan Burghofer et autres

de, at (code pays fourni par la source)

68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Helena Lanzafame, Ilektra A. Mavroeidi, Kim Magaly Pabst, Mélanie Desaulniers et autres

Fibroblast activation protein-α (FAP) is often highly expressed by sarcoma cells and by sarcoma-associated fibroblasts in the tumor microenvironment. This makes it a promising target for imaging and therapy. The level of FAP expression and the diagnostic value of 68Ga-FAP inhibitor (FAPI) …

de, ca (code pays fourni par la source)

212P Correlation of 68Ga-SSO120 PET with SSTR2 expression and prognostic value in patients with small cell lung cancer

Ilektra A. Mavroeidi, David Kersting, Agnieszka Romanowicz, T. Haake et autres

Positron Emission Tomography (PET) imaging of the somatostatin receptor 2 (SSTR2)-antagonist satoreotide trizoxetan (SSO120, previously OPS202) is a novel technique for accurate staging of patients with small cell lung cancer (SCLC). Here, we evaluate the prognostic value of 68Ga-SSO120 PET at initial …

de (code pays fourni par la source)

109P DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?

Ilektra A. Mavroeidi, Timm M. Reißig, Stavros Kalbourtzis, S-T. Liffers et autres

de (code pays fourni par la source)

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim Magaly Pabst, Lukas Kessler, Pedro Fragoso Costa et autres

Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities